GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

The global Healthcare Contract Manufacturing Market size is projected to be valued at USD 183.7 billion in 2023 and reach USD 347.5 billion by 2030, growing at a CAGR of 9.5% according to a new report ...

Journalists and news professionals across Canada today are launching an industry-wide mental health support program to combat stress, burnout and trauma exposure. Twenty volunteers were trained this ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

GSK is a rival drugmaker.House Judiciary Chair Jim Jordan sent a letter Thursday to Dormitzer seeking documents and information as well as his testimony in a transcribed interview. The letter ...

The FDA has lifted its 19-month clinical hold on vaginal yeast infection drug Brexafemme (ibrexafungerp), according to the treatment's developer Scynexis. In its first-quarter report, the Jersey ...

GSK GSK2.07%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

[LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker seeks to shore up its pipeline of new medicines. The treatment developed by ...

GSK Plc agreed to buy an experimental medicine for as much as $2 billion to shore up its drug pipeline and muscle into the promising field of liver therapies. The treatment is ready to enter the last ...

(RTTNews) - GSK plc (GSK, GSK.L) has entered into an agreement to acquire Boston Pharmaceuticals' BP Asset IX Inc. for $2 billion in total cash consideration, comprising a $1.2 billion upfront ...